Beta-glucan for non-small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether beta-glucan, a supplement taken by mouth, can help people with non-small cell lung cancer. You may be able to join if you’re newly diagnosed (no recent treatment) and can safely take pills.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (either suspected or confirmed)
- You have not had cancer treatment in the last 6 months (treatment-naive)
- You can swallow pills and take the study supplement by mouth
- Your energy/function level is fair to moderate (ECOG 0 to 3 for the first group, 0 to 2 for the surgery group)
- Your white blood cell count is high enough (ANC at least 1500)
- You can sign consent and understand the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
This trial studies whether the herbal medicine HGXJT can improve outcomes and safety for people with non-small cell lung cancer that has spread to the bones. It is designed for a specific lung cancer type (EGFR and ALK wild type) and people who have not had certain immune treatments before.
This Phase 2 study tests a combination of two experimental medicines in people with advanced or metastatic solid cancers, including non-small cell lung cancer and nasopharyngeal cancer. It aims to see whether the drugs can shrink tumors and improve outcomes, while carefully checking safety and eligibility.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This study tests a new cell therapy (BST08) for people with advanced non-small cell lung cancer that has not improved after at least two prior treatments. The treatment is made from a sample of your own tumor, so it may be a personalized option for you.
This trial tests PLB1004, an oral medication that targets a specific gene mutation (EGFR) in non-small cell lung cancer. It may be an option if you have this mutation and are looking for a new treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.